glutamic oxaloacetic transaminase 45 (<35) U/L and serum glutamic pyruvic transaminase 57 (<35) U/L. Rest of routine investigations were within normal limits. Since the patient had a long latent period between the intake of drug and onset of rash, urticated papular exanthem, facial edema, fever, eosinophilia, leukocytosis, and raised liver enzymes, the patient was diagnosed as a possible case of DRESS syndrome according to RegiSCAR (European Registry of Severe Cutaneous Adverse Reaction) criteria. [3] Culprit drug was thought to be lamotrigine as aromatic group of drugs cause DRESS more frequently. All medicines were stopped and the patient was started on oral steroids as 1 mg/kg body weight which was then tapered gradually over a period of 6 weeks along with antihistamines. There was subsidence of rash with normalization of liver function tests and absolute eosinophil count. After 2 weeks, the patient again visited the same psychiatrist. This time, lamotrigine was avoided, and the patient was again put on lithium. After 3 days, the patient developed similar rash with facial edema. This time, liver function tests were normal, but total leukocyte count was 14,900/mm 3 and absolute eosinophil count 1300/μl. On reexposure to lithium, patient developed similar episode within a short time interval. Hence, the diagnosis was changed to DRESS syndrome secondary to lithium. The patient was started on oral steroids which were gradually tapered in 4 weeks and antihistamines. This was followed by improvement in rash and normalization of counts.
Shreedhar et al. also described a patient of DRESS syndrome secondary to lithium. [4] Although aromatic group of anticonvulsants are the main culprits in DRESS syndrome, possibility of DRESS syndrome secondary to lithium should also be kept in mind because early withdrawal of the offending drug may avoid a life-threatening complication.
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A Case of Cutaneous T-cell

, Nidhi Sharma
Sir, A 43-year-old male patient presented with generalized pruritic, erythematous to violaceous plaques and hypopigmented scaly ill-defined patches. The patient was treated for psoriasis for the past 20 years, by various doctors in tertiary centers, with topical steroid, The patient's condition further worsened, and he developed multiple new plaques in the past 6 months. He sought treatment from another hospital in Southern India and was prescribed secukinumab (Injection Scapho™) loading dose (five injections at weekly interval). After the fifth injection of secukinumab, the patient showed no improvement.
After this development, he came to our hospital for the second opinion of whether he should be continuing the injection.
On examination, we noticed that he had many erythematous to violaceous plaques and nodular lesions in face, trunk, and extremities, some of which showed signs of crusting in the center [ Figure 1 ]. He also had scaly ill-defined patches spread over the trunk and extremities; on careful history taking, it was revealed that these scaly patches were there for more than 25 years, and his plaque developed much later.
We asked the patient to stop secukinumab injections for the time being and asked for the routine blood counts and serology, which was within normal limit. We did a 4 mm skin punch biopsy from the plaque, and on hematoxylin and eosin staining, the histopathology revealed epidermotropism with atypical lymphocytes in clusters throughout the epidermis [ Figure 2a and b]. Immunohistochemistry revealed clonal proliferation of CD2, CD3, and CD5 positive and CD20 and CD7 negative lymphocytes in epidermis and superficial dermis [ Figure 3a -e]. Fludeoxyglucose whole-body positron emission tomography/computed tomography scans revealed bilateral involvement of axillary, external iliac, and inguinal lymph node. Peripheral blood smear, however, failed to detect any atypical T-lymphocyte. We diagnosed the case as cutaneous T-cell lymphoma (CTCL), and currently, the patient is undergoing chemotherapy in a tertiary cancer hospital.
We report this case to draw attention to this unusual situation when more than one biologics were used in a patient with a provisional diagnosis of psoriasis. CTCL can be a great mimicker of many diseases including psoriasis. Many dermatologists treated the patient with multiple immunosuppressives and immunomodulators, and a battery of tests was conducted. However, somehow, no one considered doing a biopsy even after repeated failure of systemic therapies including biologics.
CTCL can mimic psoriasis in different stages as it may produce psoriasiform plaques [1] or acquired palmoplantar keratoderma [2] and erythroderma. [3] Moreover, even histopathologically, early CTCL may be difficult to be differentiated from psoriasiform dermatitis. [4] CTCL has been described in patients of psoriasis; [5] especially, there can be a sudden onset of cutaneous lymphoma, after initiation of immunosuppressives. [6] Systemic hepatosplenic T-cell lymphoma was also reported with immunomodulators and biologics in a patient with Crohn's disease. [7] It is reported in literature that there is a definite risk of developing lymphoma in the patients of psoriasis. [8] There was a suggestion of genetic linkage in the pathogenesis of psoriasis and CTCL. [9] Hence, we conclude that CTCL can not only be masquerading as psoriasis both clinically and histopathologically but also there can be some causal linkage. CTCL was reported in patients of psoriasis who were treated with biologicals such as etanercept [10] and efalizumab. [11] Keeping in mind the above discussion and the context of our patient, we strongly suggest that a biopsy for histopathology should be considered in cases of recalcitrant psoriasis, especially before starting biological therapy.
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Sir, Cutaneous leishmaniasis (CL) is a parasitic disease caused by the intracellular protozoan Leishmania and transmitted by the bite of an infected sand fly belonging to the genus Phlebotomus or Lutzomyia. There are estimated 12 million cases worldwide, with 1.5 million new cases being reported annually. In India, the disease has been reported from the hot and dry areas of Rajasthan and Gujarat, with indigenous cases being reported from Kerala, Assam, Haryana, and now recently from Himachal Pradesh, where it is mainly caused by Leishmania tropica. [1, 2] There has been an upsurge in the incidence of CL in this part of the country over the past few years. Most of our patients hailed from two districts of the valley -Kupwara and Baramulla, all located along the northwestern frontier of Kashmir valley and with Kupwara sharing its border with Pakistan-administered Kashmir. Unlike the rest of the valley which is known for cool temperature during summers rarely exceeding 35°C, these areas possess the distinction of having warmer and dry climate. All the affected patients came from low socioeconomic strata, dwelling in mud houses with no proper protection from insect exposure. Moreover, predominant outdoor occupations such as animal rearing and farming accounted for the exposed fraction of population to high risk of the disease.
